Physician profile
Deborah Willa Risa
NPI 1417258930
$1,680.87
in general payments reported to CMS, 2019-2025
11 companies · $84.27 in 2025
The $84.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $235 · 2023: $468 · 2024: $554 · 2025: $84.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.72 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $588.13 | 2021-2025 | |
| Inspire Medical Systems, INC. | $263.14 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $240.34 | 2023-2025 | Sunosi |
| Glaxosmithkline, LLC. | $196.90 | 2021-2025 | Nucala |
| Harmony Biosciences LLC | $171.18 | 2022-2024 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $58.24 | 2024 | Lumryz |
| Zoll Respicardia, INC. | $40.88 | 2024 | Remede System |
| Astrazeneca Pharmaceuticals LP | $37.71 | 2021 | |
| Genentech USA, INC. | $34.29 | 2023 | Xolair |
| Kaleo, INC. | $33.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2023 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Risa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.